Tag Archives: Abemaciclib with endocrine therapy

1 Recommendations 1.1 Abemaciclib with endocrine therapy is recommended, within its marketing authorisation, as an option for adjuvant treatment of hormone receptor-positive, HER2-negative, node‑positive early breast cancer in adults whose disease is at high risk of recurrence, defined by the following clinical and pathological features: at least 4 positive axillary lymph nodes, or 1 to 3 […]